10.53
-0.09 (-0.85%)
| Penutupan Terdahulu | 10.62 |
| Buka | 10.51 |
| Jumlah Dagangan | 505,104 |
| Purata Dagangan (3B) | 2,302,311 |
| Modal Pasaran | 906,079,104 |
| Harga / Jualan (P/S) | 21.78 |
| Harga / Buku (P/B) | 4.44 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Jul 2025 - 4 Aug 2025 |
| Margin Operasi (TTM) | -416.67% |
| EPS Cair (TTM) | -3.85 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 160.71% |
| Nisbah Semasa (MRQ) | 5.80 |
| Aliran Tunai Operasi (OCF TTM) | -286.52 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -169.65 M |
| Pulangan Atas Aset (ROA TTM) | -36.29% |
| Pulangan Atas Ekuiti (ROE TTM) | -93.70% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Syndax Pharmaceuticals, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 2.00 |
|
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.30% |
| % Dimiliki oleh Institusi | 120.82% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 41.00 (JP Morgan, 289.36%) | Beli |
| Median | 32.00 (203.89%) | |
| Rendah | 17.00 (Scotiabank, 61.44%) | Pegang |
| Purata | 30.00 (184.90%) | |
| Jumlah | 2 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 11.79 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Guggenheim | 06 May 2025 | 32.00 (203.89%) | Beli | 10.64 |
| Scotiabank | 06 May 2025 | 17.00 (61.44%) | Pegang | 10.64 |
| JP Morgan | 20 Mar 2025 | 41.00 (289.36%) | Beli | 14.10 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |